Found 1,003 articles
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis.
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE).
Dr. Janet Hoogstraate New Board Member of AlzeCure Pharma
AlzeCure Pharma AB announced that Janet Hoogstraate is newly elected to AlzeCure's board.
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease- First Human Evidence that CT1812 Selectively Engages Aβ Oligomers
Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “A Phase 1b Randomized Clinical Trial of CT1812 to Measure Aβ Oligomer Displacement in Alzheimer’s Disease Using an Indwelling CSF Catheter” (doi: 10.1186/s40035-023-00358-w) has been published in the journal, Translational Neurodegeneration.
ImmunoBrain Checkpoint Doses First Patients in Phase 1b Clinical Trial of IBC-Ab002 for Alzheimer's Disease
ImmunoBrain Checkpoint Inc. today announced that it has dosed the first two patients in the Phase 1b IBC-01-01 clinical trial investigating IBC's lead program, IBC-Ab002 for patients with early Alzheimer's disease.
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
Coya Therapeutics, Inc. today reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with AD.
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease.
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
First Wave BioPharma, Inc. announced that it has completed patient screening in its ongoing Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.
SYNAPS Dx Resolves Alzheimer’s Disease Diagnostic Dilemma: White Paper Documents Improved Diagnostic Pathway with Highly Accurate, Accessible Skin Test
SYNAPS Dx, a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease, is pleased to announce the release of its white paper, “Resolving a Diagnostic Dilemma.”
While donanemab showed impressive results in Phase III TRAILBLAZER-ALZ 2, concerns regarding its safety remain compared with Biogen’s and Eisai’s Leqembi.
Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
Quest Diagnostics today announced nationwide availability of the RestoreU ™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.
The amyloid plaque targeting therapy met primary endpoint and all secondary endpoints, which Lilly will use in its submission to the FDA this quarter.
ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab
The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eli Lilly and Company for their amyloid-clearing antibody donanemab.